Eckart Bartnik
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eckart Bartnik.
Matrix Biology | 2000
Christine Hörber; Frank Büttner; Christopher Kern; Gerno Schmiedeknecht; Eckart Bartnik
Aggrecanase cleavage at the Glu(373)-Ala(374) site in the interglobular domain of the cartilage proteoglycan aggrecan is a key event in arthritic diseases. The observation that substrates representing only the aggrecanase cleavage site are not catabolized efficiently by aggrecanase prompted us to investigate the requirement of aggrecanase for additional structural elements of its substrate other than the actual cleavage site. Based on the recombinant substrate rAgg1mut we constructed deletion mutants with successively truncated N- or C-termini of the interglobular domain. Catabolism by aggrecanase activities induced in rat chondrosarcoma cells, porcine chondrocytes, and by human recombinant ADAMTS4 showed a gradually decreasing catabolism of progressively shortened, N-terminal deletion mutants of the substrate rAgg1mut. A reduction to 32 amino acids N-terminal to the aggrecanase site resulted in a decrease of at least 42% of aggrecanase cleavage products as compared with the wild-type substrate. When only 16 amino acids preceded the Glu(373)-Ala(374) site, aggrecanase cleavage was completely inhibited. In contrast, C-terminal deletions did not negatively affect aggrecanase cleavage up to the reduction to 13 amino acids C-terminal to the cleavage site. Unlike aggrecanase(s), membrane type 1-matrix metalloprotease (MT1-MMP), able to cleave rAgg1mut both at the aggrecanase and the MMP site, was insensitive to N-terminal deletions regarding aggrecanase cleavage, indicating that the importance of the N-terminus is characteristic for aggrecanase(s). Taken together, the results demonstrate that the amino-terminus of rAgg1mut, containing the MMP site, plays an important role for efficient cleavage by aggrecanase(s), possibly by serving as a further site of interaction between the enzyme and its substrate.
Arthritis & Rheumatism | 2002
Brigitte Bau; Pia M. Gebhard; Jochen Haag; Thomas Knorr; Eckart Bartnik; Thomas Aigner
Archive | 1996
Werner Thorwart; Wilfried Schwab; Manfred Schudok; Burkhard Haase; Eckart Bartnik; Klaus-Ulrich Weithmann
Archive | 1995
Werner Thorwart; Wilfried Schwab; Manfred Schudok; Burkhard Haase; Eckart Bartnik; Klaus-Ulrich Weithmann
Archive | 1997
Alexander Toepfer; Gerhard Kretzschmar; Eckart Bartnik; Christoph Dr. Hüls; Dirk Dr Seiffge
Archive | 2003
Hans Ulrich Stilz; Volkman Wehner; Jochen Knolle; Eckart Bartnik; Christoph Dr Huels
Archive | 1997
Eckart Bartnik; Bernd Eidenmueller; Frank Buettner; Bruce Caterson; Clare Hughes
Archive | 2001
Christopher Kern; Christine Hoerber; Eckart Bartnik; Philipp Haus-Seuffert
Archive | 1997
Brigitte Dr Hoersch; Michael Ahlers; Gerhard Kretzschmar; Eckart Bartnik; Dick Seiffge
Archive | 1999
Manfred Schudok; Wilfried Schwab; Gerhard Zoller; Eckart Bartnik; Frank Büttner; Klaus-Ulrich Weithmann